Literature DB >> 18791547

Relationship of diabetic macular oedema with glycosylated haemoglobin.

T-H Chou1, P-C Wu, J Z-C Kuo, C-H Lai, C-N Kuo.   

Abstract

PURPOSE: To evaluate the correlation between glycosylated haemoglobin (HbA1c) and central foveal thickness as measured by optical coherence tomography (OCT) in patients with diabetes.
METHODS: Retrospectively review of medical records of central foveal thickness as measured by OCT and laboratory data of glycosylated haemoglobin. HbA1c was compared with foveal thickness measured by OCT within the preceding 3 months. Clinically significant macular oedema (CSME) was diagnosed if central foveal retinal thickness was greater than 325 mum in OCT.
RESULTS: One hundred and two eyes of 102 patients were included in this cross-sectional study. Univariate analysis revealed that the CSME diagnosed by OCT in diabetes was not statistically significant with sex, right or left eye, DM duration over 10 years or not, and AC sugar level (over 140 or not). The HbA1C level (8 or over) and age (50 or less) showed a significant (P=0.005 and 0.006, respectively) and positive association with macular thickness in OCT. A trend towards higher risk was seen for factors of age <or=50 and HbA1c >or=8%.
CONCLUSIONS: Patients with HbA1c of 8 or above had an increase in macular thickness in type 2 diabetic eyes and there was a statistical significant correlation between younger age, shorter DM duration and thicker macular thickness. Strict sugar control decreased the risk of diabetic macular retinopathy, and OCT could be an excellent detector of early diabetic macular oedema.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18791547     DOI: 10.1038/eye.2008.279

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  18 in total

1.  Qualitative and quantitative OCT response of diffuse diabetic macular oedema to macular laser photocoagulation.

Authors:  R Vemala; S Koshy; S Sivaprasad
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

2.  Influence of diabetes on macular thickness measured using optical coherence tomography: the Singapore Indian Eye Study.

Authors:  C C A Sng; C Y Cheung; R E Man; W Wong; R Lavanya; P Mitchell; T Aung; T Y Wong
Journal:  Eye (Lond)       Date:  2012-02-17       Impact factor: 3.775

3.  Blood pressure, vessel caliber, and retinal thickness in diabetes.

Authors:  Wendy W Harrison; Ann Chang; Maria G Cardenas; Marcus A Bearse; Marilyn E Schneck; Shirin Barez; Anthony J Adams
Journal:  Optom Vis Sci       Date:  2012-12       Impact factor: 1.973

4.  Five-year visual outcome following laser photocoagulation of diabetic macular oedema.

Authors:  S Jyothi; S Sivaprasad
Journal:  Eye (Lond)       Date:  2011-05-13       Impact factor: 3.775

5.  Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy.

Authors:  Yoshifumi Okamoto; Fumiki Okamoto; Takahiro Hiraoka; Tetsuro Oshika
Journal:  Jpn J Ophthalmol       Date:  2014-04-29       Impact factor: 2.447

6.  Predictive factors for patients receiving intravitreal anti-vascular endothelial growth factor for the treatment of diabetic macular edema.

Authors:  Robert M Carroll; Yinxi Yu; Brian L VanderBeek
Journal:  Eur J Ophthalmol       Date:  2019-02-14       Impact factor: 2.597

7.  Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema.

Authors:  Ning Dong; Bing Xu; Liqun Chu; Xin Tang
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

8.  Central macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy.

Authors:  Mehmet Demir; Ersin Oba; Burcu Dirim; Erhan Ozdal; Efe Can
Journal:  BMC Ophthalmol       Date:  2013-04-09       Impact factor: 2.209

9.  Cental Macular Thickness in Patients with Type 2 Diabetes Mellitus without Clinical Retinopathy.

Authors:  Mehmet Demir; Burcu Dirim; Zeynep Acar; Murat Yılmaz; Yekta Sendul
Journal:  J Ophthalmol       Date:  2013-04-03       Impact factor: 1.909

10.  Risk Factors for Refractory Diabetic Macular Oedema after Sub-Tenon's Capsule Triamcinolone Acetonide Injection.

Authors:  Toshiyuki Oshitari; Yuta Kitamura; Sakiko Nonomura; Miyuki Arai; Yoko Takatsuna; Eiju Sato; Takayuki Baba; Shuichi Yamamoto
Journal:  J Ophthalmol       Date:  2015-09-20       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.